The effect of resveratrol on the expression of MDR1 gene in leukemic lymphoblast’s of acute lymphoblastic leukemia patients

Abstract

Background: Chemotherapy plays a very important role in the treatment of leukemia but the resistance properties of the lymphoblasts limit the effect of chemotherapy. One of the main mechanisms of resistance to chemotherapy is the increased expression of MDR1 gene. The aim of this study was to explore the effect of resveratrol on the expression of MDR1 gene in leukemic lymphoblast of new cases of acute lymphoblastic leukemia (ALL) patients in vitro.

Methods: Separation of lymphoblasts of 5 new case ALL patients from peripheral blood was performed by ficoll density gradient centrifugation. Lymphoblasts were cultured in RPMI 1640 medium. Lymphoblasts were treated with 50µmol/L resveratrol for 48 h. Total RNA was extracted with guanidine isothiocyanate. RNA was converted to cDNA. Real time PCR was used to detect mRNA expression of MDR1.

Results: The results of gene detection showed that the expression of MDR1 did not change significantly in the patients however, in one patient expression of MDR1 increased upon treatment with resveratrol.

Conclusion: The results of this study did not support resveratrol as a compound to reverse multidrug resistance in leukemic lymphoblasts.

Keywords: Resveratrol, Multidrug resistance gene, Leukemic lymphoblast, ALL
Resveratrol has a dose-dependent effect on mitotic and apoptotic activity of endothelial and tumor cell lines, while the low dose of resveratrol enhance cell proliferation; higher doses induce apoptosis and decrease mitotic activity (10). Resveratrol is known to have potent anti-inflammatory and antioxidant effects and inhibits the growth of a variety of cancer cells (11). In this research, we evaluated the effect of resveratrol on the expression of MDR1 gene in leukemic lymphoblasts of new case ALL patients in vitro.

**Methods**

5 new ALL patient cases were enrolled in the study after filling out the informed consent form. All patients had more than $100 \times 10^3 / \mu l$ white cells in peripheral blood with up to 80% blasts. Samples were obtained before starting chemotherapy. Mononuclear cells were separated from 3ml of peripheral blood of the patients with the use of fycol and centrifuge.

**Cell culture:** Cells were grown in RPMI 1640 medium (Gibco, Invitrogen, USA), under sterile condition. Cells were incubated in a humidified 5% CO2 incubator at 37°C. The lymphoblasts of each patient were divided into two parts and cultured in separated cell culture T-25 flasks in which one of them was the group treatment with resveratrol and the control group.

**Treatment of the cells with resveratrol:** Resveratrol with the concentrations of 50 µmol/L was added to the flasks then incubated in 37°C and 5% CO2 incubator. After 48 h of incubation, the total RNA was extracted then reversely transcribed into cDNA using an ExScriptRT reagent kit (Biioneer). primers: MDR1(87bp) sense 5´-CGGGAGCAGTCATCTGTGGT-3´ antisense 5´-CAAGAGAGCGAAGCGCTG-3´; β-actin (160 bp) sense 5´-AGA ACA TCA TCC ATG CAT CCA-3´, antisense 5´-GCC TGC TTC ACC ACC TTC TTG-3´. Real-time-PCR conditions were set as follows: 94° C for 10 min, 45 cycles at 94 °C for 30 s, 58 °C for 30 s, and 72° C for 35 s; followed by extension at 72 °C for 10 min. All the data were processed with SPSS13.0. One-factor variance analysis (ANOVA) was used in the comparison of several concentrations and the significance of difference was indicated as p<0.05.

**Results**

The relative expression of MDR1 gene was analyzed by Real-time-PCR. After 48 h treatment with 50 µmol/L of resveratrol, the expression of MDR1 gene was not changed significantly in lymphoblasts in 4 patients and was in the range of 1.087 to 1.3 times, but in one patient increased upon treatment (3.335 times) (fig 1).

**Discussion**

MDR1, express P-glycoprotein, a transmembrane carrier that exports hydrophobic substrates and most chemotherapy drugs out of the cells especially tumor cells. A growing body of literature indicates that resveratrol, a plant constituent enriched with the skin of grapes (12), is one of the promising agents for the prevention of heart disease. Similarly to other polyphenols resveratrol exerts an antioxidant effect (13). In addition resveratrol acts as an antioxidant (10, 14). Belaszenda demonstrated that resveratrol has a dose-dependent effect on mitotic and apoptotic activity of endothelial and tumor cell lines. They showed that low doses of resveratrol enhance cell proliferation; higher doses induce apoptosis and decrease mitotic activity. Fang Guan assessed the effect of resveratrol on the expression of MDR1 gene in human oral epidermis KBv200 cell line and showed that resveratrol could down-regulate MDR1 gene (15). But the results of our study showed that the expression of MDR1 gene was not changed significantly in the lymphoblasts of 4 patients and in one patient increased upon treatment. The reason for these unexpected results is not entirely clear. It may also be because the concentration used for treatment, was low. Also 48 h treatment with resveratrol may be not...
sufficient for resveratrol to take effect on gene expression. Furthermore, we supplemented the culture medium with fetal bovine serum which may interfere with gene expression. Furthermore, the MDR1 gene expression in one patient is very high in comparison to other patients as you can see in figure 1 (3.335 times). This high change may be the under effect of genetic differences or special translocations. Resveratrol may have different effects in the upper concentrations that need to be assessed in the future.

In conclusion, we did not find any sign in support of resveratrol as a compound reversing multidrug resistance in leukemic lymphoblasts.

Acknowledgments

The authors would like to thank the staff of Hematology and Oncology Research Center for their sincere cooperation in performing the study.

Funding: This research was funded by the Hematology and Oncology Research Center of Tabriz University of Medical Sciences.

Conflict of Interest: There is no conflict of interest.

References

1. Miladpoor B, Tavassoli A, Meshkibaf MH, Kha F. Evaluation of C3435T MDR1 gene polymorphism in adult patient with acute lymphoblastic leukemia. J Med 2011; 12: 3-6.
2. Shukla S, Chufan EE, Singh S, et al. Elucidation of the structural basis of interaction of the BCR-ABL kinase inhibitor, nilotinib (Tasigna) with the human ABC drug transporter P-glycoprotein. Leukemia 2014; 28: 961-4.
3. Mohammadzadeh R, Baradaran B, Valizadeh H, Yousefi B, Zakeri-Milani P. Reduced ABCB1 expression and activity in the presence of acrylic copolymers. Adv Pharm Bull 2014; 4: 219-24.
4. Choi CH. ABC transporters as multidrugresistance mechanisms and the development of chemosensitizers for the irrevocable. Cancer Cell Int 2005; 5: 30.
5. Teodori E, Dei S, Martelli C, Scapechi S, Gualtieri F. The functions and structure of ABC transporters: implications for the design of new inhibitors of P-glycoprotein and MRP1 to control multidrug resistance (MDR). Curr Drug Targets 2006;7: 893-909.
6. Kitagawa S. Inhibitory effects of polyphenols on P-glycoprotein-mediated transport. Biol Pharm Bull 2006; 29: 1-6.
7. Borowski E, Bontemps-Gracz MM, Piwkowska A. Strategies for overcoming ABC-transporters-mediated multidrug resistance (MDR) of tumor cells. Acta Biochim Pol 2005; 52: 609-27.
8. Savouret JF, Quesne M. Resveratrol and cancer: a review. Biomed Pharmacother 2002; 56: 84-7.
9. Siemann EH, Creasy LL. Concentration of the phytoalexin resveratrol in wine. Am J Enol Vitic 1992; 43: 49-52.
10. Szende B, Tyihák E, Király-Véghely Z. Dose-dependent effect of resveratrol on proliferation and apoptosis in endothelial and tumor cell cultures. Exp Mol Med 2000; 32: 88-92.
11. Athar M, Buck JH, Tang X, et al. Resveratrol: A review of preclinical studies for human cancer prevention. Toxicol Appl Pharmacol 2007; 224: 274-83.
12. Király-Véghely Z, Tyihák E, Albert L, Németh ZI, Kátay G. Identification and measurement of resveratrol and formaldehyde in parts of white and blue Berries. Acta Biol Hung 1998; 49: 281-9.
13. Frankel EN, Waterhouse AL, Kinsella JE. Inhibition of human LDL oxidation by resveratrol. Lancet 1993; 341: 1103-4.
14. Tyihák E, Albert L, Németh ZI, et al. Formaldehyde cycle and natural formaldehyde generators and capturers. Acta Biol Hung 1998; 49: 225-38.
15. Quan F, Pan C, Ma Q, Zhang S, Yan L. Reversal effect of resveratrol on multidrugresistance in KBv200 cellline. Biomed Pharmacoth 2008; 62: 622-9.